28 results about "Hematological sample" patented technology

The application relates to the technical field of blood drug concentration detection, and discloses a blood drug concentration analysis method based on mass spectrometric detection, which comprises the following steps: adopting microfluidic technology in combination with solid-phase extraction to pretreat a blood sample to obtain a concentrated solution, so as to remove interfering components and concentrate target drug molecules; according to the physicochemical properties of the target drug molecules, the concentrated solution is selected to flow through a biosensor or is directly introduced into a chromatographic unit, and the target drug molecules in the liquid phase are converted into gas-phase ions when flowing through the biosensor; chromatography-mass spectrometry is adopted to detect the gas-phase ions or the concentrated solution, so as to obtain mass spectrum data; a machine learning model is used to analyze the spectrum data, to identify the drug types and calculate the concentration of the target drug molecules, and to generate an analysis report. The method is suitable for target drugs with different physicochemical properties, simplifies the detection process, and improves the applicability and accuracy of detection.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

The objective is to provide a simple and indirect method for estimating the rate of senescent immune cells (the ratio of immune cells with high SAβgal expression levels among T cells whose surface marker is CD8-positive) using a small amount of blood sample. [Solution] This method estimates the rate of senescent immune cells using the relative expression levels of one or more selected from Granzyme K, α-Klotho, GDF15, PAI-1 (SERPIN1), and ferritin in the blood.

Viscoelastic coagulation monitoring systems having two glass discs mounted on flexible plastic arms for receiving a sample of blood therebetween, and an analyzer configured to measure a coagulation response of the sample of blood to determine whether the sample of blood indicates a hypercoagulable state in a HS patient are provided. The system may cause movement of a first glass disc relative to a second glass disc at a sufficient speed to cause coagulation of the sample of blood, and the analyzer may measure various parameters of the coagulation response including, e.g., Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (a-angle), Maximum Clot Firmness (MCF), Amplitude at 10 and 20 minutes (A10, A20, respectively), Lysis Index at 30 and 45 minutes (LI30 and LI45, respectively), indicative of a hypercoagulable state in a HS patient.

The application discloses a nucleic acid absolute quantification method based on nucleic acid constant temperature amplification, which comprises the following specific steps: step one, sample pretreatment, blood samples and saliva samples are pretreated respectively; step two, reaction system configuration and assembly; step three, digital micro-reaction unit preparation and amplification; and step four, multiple signal analysis and absolute quantification. In the application, multiple primer design and a double-probe system are adopted, so that the mutation detection rate is improved, and the detection limit can be reduced to 0.1% variation through Cas12a-sgRNA auxiliary verification. The double-emulsification technology of the micro-fluidic chip is adopted, so that the droplet diameter variation coefficient is controlled within 5%, and the clogged micropore rate is reduced by real-time analysis of the micropore array image through the ImageJ software, automatic marking and exclusion of abnormal units.

The invention provides methods of determining the neutrophil level in a sample by determining the level of CD16b, including the intracellular form of CD16b in a sample, such as a blood sample. The methods may further comprise the determination of lactate levels Also provided are associated diagnostic and therapeutic methods. Further provided are kits and devices for performing the methods, particularly lateral flow kits and devices.

This application relates to a blood cell analyzer and a red blood cell detection method. The blood cell analyzer includes: a sampling device for aspirating a blood sample to be tested; a sample preparation device for mixing a portion of the blood sample to be tested with a diluent to prepare a test sample; an impedance detection device including a counting cell and a detection component, wherein the counting cell is for the test sample to pass through, and the detection component is for acquiring the electronic signals of each particle in the test sample as it passes through the counting cell; and a processor configured to: acquire raw red blood cell volume distribution information based on the electronic signals of each particle in the test sample; acquire red blood cell agglutination information based on the raw red blood cell volume distribution information; and obtain the red blood cell count value of the blood sample to be tested based on the raw red blood cell volume distribution information and the red blood cell agglutination information. This enables the acquisition of an accurate red blood cell count value.

Provided is a measurement device that can continue measurement without stopping the measurement device even when the processing capacity of the device is improved and the consumption of reagents increases. The measurement device includes a first container that contains a diluent, a second container that contains a hemolytic agent, a measurement unit, a supply unit, and a control unit. The measurement unit includes a third container that can contain a staining solution, a first chamber for mixing the diluent and a blood sample to prepare a first test sample, a second chamber for mixing the hemolytic agent, the blood sample, and the staining solution to prepare a second test sample, and a measurement unit. The measurement unit can obtain electrical signals and optical signals of 300 or more and 500 or less samples per hour for measurement instructions for a first measurement item and a second measurement item, and obtains measurement results based on the obtained electrical signals and optical signals. The supply unit continues to supply the diluent during replacement of the first container and continues to supply the hemolytic agent during replacement of the second container.

The utility model provides a kind of oscillation device for blood protein detection, it is related to blood protein detection field, including oscillation unit, including the oscillation generation box for generating oscillation movement, the cover fixedly connected in the top of the oscillation generation box, the spring fixedly connected in the bottom of the inner chamber of the cover four around, the oscillation platform fixedly connected in the top of the spring, and the tube groove for limiting placement test tube being opened in the top of the oscillation platform;The utility model is through the design of limiting component, especially the cooperation of screw rod, pressing plate, pad and rubber pad, can effectively close and limit the top of test tube, prevent blood leakage due to oscillation force and liquid inertia in the process of oscillation, to avoid sample waste and experimental environment pollution, by the cooperation of the oscillation generation box in oscillation unit, oscillation platform and spring, can make oscillation more stable and uniform, help to improve the mixing effect of blood sample, ensure the accuracy and reliability of detection result.

This invention provides an electrochemical glucose sensor for continuous blood glucose monitoring, belonging to the field of biochemical sensing technology. The sensor includes a substrate and a three-electrode system, wherein the three-electrode system includes a working electrode, a reference electrode, and an auxiliary electrode. The working electrode comprises a conductive substrate, and an electrocatalytic enzyme composite layer and an outer membrane layer sequentially modified on the surface of the conductive substrate, with the outer membrane layer covering the outside of the electrocatalytic enzyme composite layer. The electrocatalytic enzyme composite layer is composed of glucose oxidase, an electron mediator, and a cross-linking agent. The glucose oxidase and the electron mediator are cross-linked and fixed to the surface of the conductive substrate by the cross-linking agent. This invention solves the technical problems of traditional electrochemical glucose sensors, such as long detection time, limited linear response range, low sensitivity and high detection limit, poor stability due to short-term signal drift, weak resistance to interference from sugar impurities and endogenous electroactive small molecules, and poor linearity and large detection error when directly detecting blood samples.

Methods and systems for determining recurrence of a tumor in a subject using mutational profiles derived from cell-free DNA obtained concurrently with or prior to tumor resection and integrating mutational profiles from the resected tumor to enhance classification models. Low-depth whole-genome sequencing data can be used to obtain a variety of molecular profiles, including genetic and epigenetic profiles, from tumor tissue and blood samples obtained after the tumor is resected from the subject. The methods may also comprise using a classifier trained to recognize mutational profiles from subjects exhibiting minimal residual disease (MRD) to determine whether a tumor recurred in a subject.

The embodiments of the present application relate to a platelet counting method and a blood cell analyzer. The method comprises: aspirating a blood sample to be tested; mixing one portion of said blood sample with a diluent to prepare a first test sample, and mixing the other portion of said blood sample with a hemolytic agent and fluorescent dye to prepare a second test sample; performing impedance measurement on the first test sample, in order to obtain an electrical signal of the first test sample; performing optical measurement on the second test sample, in order to obtain at least one optical signal from among a scattered light signal and a fluorescent light signal of the second test sample; at least on the basis of the electrical signal of the first test sample, obtaining platelet distribution information of said blood sample; and at least on the basis of the pulse width of an optical signal among the at least one optical signal that corresponds to platelets in the second test sample, and the platelet distribution information, obtaining a platelet count value. Thus, an accurate platelet count can be obtained at a low cost.

The present disclosure provides a fully human therapeutic monoclonal antibody or fragment thereof, which is a fully human antibody specifically binding to the RBD region of SARS-CoV-2 S protein obtained from isolating a single B cell clone from a convalescent blood sample of a Covid-19 patient, which does not produce ADE effect on SARS-CoV-2 infection of THP-1 cells and K562 cells. The monoclonal antibody has high affinity to the RBD of SARS-CoV-2 S protein, with a KD value of 5.0 x 10 ‑9 M; and the monoclonal antibody has blocking activity to the binding of the RBD of SARS-CoV-2 S protein to ACEII, with an IC50 value less than 50 nM.

Analysis of cell populations for both research and clinical applications such as cell therapy is often performed on whole blood that is close to 24 hours old. The reason for this is that the analysis site is removed from the blood draw site so that blood must be shipped overnight to the analysis site. During the 24-hour shipping period, granulocytes and other blood components break down into undesirable cell debris including nucleic acids that are released into the blood. Such debris is known to interfere with immunological assays and with thawing following freezing of samples. The present invention solves this issue by removing granulocytes (and optionally other components) using an anti-CD15 molecule (or other appropriate molecule) bound to metallic magnetic particles. Following mixing, the granulocytes (or other components) are removed and prepared for shipment to the analysis site or for other reasons.

This invention discloses an exosome-based tumor diagnostic kit and its applications, relating to the fields of medical laboratory science and molecular diagnostics. The kit includes: exosome isolation components; exosome lysis and nucleic acid extraction components; internal standard and quantitative control components; reverse transcription components; molecular detection components; protein detection components; and interpretation and analysis components. This invention achieves complementary fusion of nucleic acid and protein information by simultaneously detecting exosome nucleic acid markers and exosome-derived protein markers from the same blood sample and employing a pre-defined normalization and weighted interpretation algorithm. This fusion strategy overcomes the problem of decreased sensitivity or specificity caused by biological heterogeneity or sample batch variations of single markers, making the identification of early or minor lesions more robust. Simultaneously, through synergistic interpretation among multiple markers, false positive signals originating from benign diseases or physiological fluctuations can be effectively suppressed, thereby improving the reliability of clinical screening and diagnosis.

The application discloses a PBMC separation and displacement method, and relates to the technical field of cell separation. The method comprises a separation stage and a displacement stage, and both the separation stage and the displacement stage adopt a centrifugal cup with one-in-two-out, which is provided with an inner port, an outer port and a central port. The separation stage comprises the following steps: pumping gradient liquid into the centrifugal cup from the outer port, then pumping blood samples into the centrifugal cup from the outer port, rotating the centrifugal cup and discharging inner-layer blood plasma from the central port, performing centrifugal separation while continuously pumping gradient liquid into the centrifugal cup from the outer port, discharging red blood cells from the inner port after centrifugal separation, then discharging red blood cells from the outer port, collecting product liquid and gradient liquid and discharging them to a product bag from the inner port to obtain a displacement liquid, and discharging waste liquid from the outer port. The displacement liquid is pumped into the centrifugal cup from the inner port, and the displacement stage is started. After the displacement is completed, washing waste liquid is discharged, and a PBMC product liquid is obtained.

The application discloses a preparation method of a ratio type electrochemical sensor for synchronous detection of total hemoglobin (tHb) and glycosylated hemoglobin (HbA 1c ) "double signal opening". The application also discloses a method for synchronous quantitative detection of tHb and HbA 1c by using the ratio type sensor, and application of the method to accurate quantitative determination of blood sugar in a whole blood sample. Experimental results show that the ratio type "double signal opening" electrochemical sensor constructed by the application has high accuracy, high selectivity, high sensitivity and good anti-interference performance, and is suitable for accurate evaluation of tHb and HbA 1c in a clinical blood sample.

Disclosed is a cell analysis system including an imaging apparatus and an image analysis apparatus. The imaging apparatus includes a stage on which a smear preparation having a blood sample from a subject smeared thereon, a microscope configured to enlarge analysis target cells in the blood sample on the smear preparation, and a camera configured to capture enlarged images of the analysis target cells. The image analysis apparatus includes a processor and a memory storing a computer program. The computer program, when executed by the image analysis apparatus, causes the image analysis apparatus to generate analysis data from the image of the respective analysis target cells captured by the imaging apparatus, input the analysis data into a classifier having a neural network structure, and classify, by use of the classifier, the respective analysis target cells into one type of blood cell among a plural types of blood cells.

A light-initiated chemiluminescence detection method, a reagent, and a use. The detection method comprises: bringing a sample to be tested into contact with a reaction system comprising a first antibody and a second antibody, so as to obtain an immune reaction product, and measuring the optical signal intensity of the immune reaction product, the first antibody and / or the second antibody directionally coupling a non-specific binding region thereof to a target substance by means of an isopeptide bond. Alternatively, an R3 reagent is added on the basis of a conventional detection method, and at least two label molecules are bound by means of a pairing molecule contained in the R3 reagent, the label molecules being carried by the first antibody in luminescent microspheres, such that the at least two luminescent microspheres are aggregated into a multimeric luminescent microsphere. The detection method can improve the detection performance of light-initiated chemiluminescence, and meet detection requirements of a low-abundance sample such as p-tau217 in a blood sample.

A device may generate, based at least on time series data of a quantity of one or more markers present in a blood sample of a subject, a dynamical system model representative of an immune system of the subject, the dynamical system model including one or more functions corresponding to a derivative of the time series data, and the generating of the dynamical system model includes performing a regression to identify, within a library of candidate functions, one or more functions for inclusion in the dynamical system model. A device may determine a steady state solution for the one or more functions included in the dynamical system model. A device may determine, based at least on the steady state solution for the one or more functions included in the dynamical system model, a stability of the immune system of the subject. Related systems and computer program products are also provided.

The application relates to a lymphocyte subpopulation and cytokine combined detection method, kit and application based on flow cytometry. The method constructs a parallel detection system of cell phenotypes and cytokines on the same flow platform, solves the signal interference problem by using spectrum compatible markers, and realizes synchronous analysis of immune cell subpopulations, immune checkpoints and multiple cytokines in trace blood samples. The scheme avoids system errors and sample waste caused by multi-platform detection, can provide a comprehensive atlas reflecting the synergistic state of cell immune structure and humoral immune function, and improves the accuracy and efficiency of clinical immune evaluation.

The application discloses a blood purification device and a medical system, the blood purification device includes a device housing, a blood purifier, a blood pipeline assembly, a power assembly and a blood component analysis assembly. The blood pipeline assembly includes a first blood pipeline connecting a human blood vessel to an inlet of the blood purifier, and a second blood pipeline connecting an outlet of the blood purifier to the human blood vessel. The power assembly includes a blood pump driving blood to flow in the blood pipeline assembly, a first replenishment pump enabling an anticoagulant solution to flow into the first blood pipeline, and / or a second replenishment pump enabling a calcium solution to flow into the second blood pipeline. The blood component analysis assembly is arranged in the device housing, and is configured to detect an acquired blood sample. With the above arrangement, it facilitates corresponding adjustments of anticoagulant drugs and calcium ions in a blood purification circuit.

This invention provides a disease identification and classification method, system, electronic device, and readable storage medium, belonging to the field of multimodal data processing. The method includes: acquiring a pre-trained cross-modal representation learning model; the cross-modal representation learning model includes at least a first graph convolutional neural network and an encoder; acquiring first metabolomics data from a blood sample of a test subject; inputting the first metabolomics data into the first graph convolutional neural network to obtain blood isomorphic features of the test subject; inputting the blood isomorphic features of the test subject into the encoder to obtain blood depth features of the test subject; and identifying and classifying the brain damage phenotype of the test subject based on the blood depth features. This invention improves auxiliary diagnostic capabilities and model generalization.

The present disclosure generally relates to various articles, systems, and methods for trapping cells, e.g., within a microfluidic device. Some aspects describe microfluidic channels that prevent certain entities such as microbial cells from flowing through the channels, while allowing certain cells (e.g., blood cells) to pass. In one set of embodiments, for example, a sample (e.g., a blood sample) having a plurality of mammalian cells and a plurality of microbial cells is flowed through the microfluidic devices described herein, resulting in retention of the microbial cells.

This invention discloses the use of miR-181a-5p as a biomarker or therapeutic target in the diagnosis and treatment of sepsis. Studies have found that the expression level of miR-181a-5p changes during the hyperimmune and immunosuppressive phases of sepsis. Analysis of blood samples from two sepsis patients (Patient 1 and Patient 2) at different time points after admission revealed a negative correlation between miR-181a-5p expression and the severity of the disease, assessed using the Sepsis-Associated Organ Failure (SOFA) score. Further in vitro experiments showed that overexpression of miR-181a-5p in mouse primary dendritic cells (DCs) can enhance the immune function of DCs by targeting TNF-α mRNA. The miR-181a-5p mimic provided by this invention can promote miR-181a-5p expression, enhance DC function, and thus effectively improve the immune function of sepsis patients.